Fosun Pharma (02196) announced that on August 16, 2024, its wholly-owned subsidiary Shanghai Henlius Biotech, signed a contract with Nanjing Bank, Shanghai Branch, under which Henlius Biotech applied for a credit line of RMB 30 million and the debt period is from June 21, 2024, to June 20, 2025. On the same day, Henlius, the direct controlling shareholder of Henlius Biotech, signed a guarantee contract with Nanjing Bank, providing a joint and several liability guarantee for the debt under the above credit line.
The news app Intelligent Finance released a statement that Fosun Pharma (02196) announced that on August 16, 2024, its wholly-owned subsidiary Shanghai Henlius Biotech and Nanjing Bank, Shanghai Branch signed a contract for the highest amount of creditor's rights, and Henlius Biotech applied for a credit line of RMB 30 million. The credit line debt period is from June 21, 2024, to June 20, 2025. On the same day, Fosun Henlius, the direct controlling shareholder of Henlius Biotech, and Nanjing Bank signed a maximum guarantee contract, providing joint and several liability guarantee for the debt under the above credit line.